Analysis reveals that synthetic lethal targeting improves outcomes in multiple myeloma by leveraging proteasome vulnerabilities.
Key Points
PSMC2 overexpression was found to confer chemoresistance in multiple myeloma through proteasome activation, and targeting it enhances treatment efficacy.
High-throughput screening identified CB-5339 as a synthetic lethal agent alongside bortezomib, improving survival in PSMC2-overexpressing tumors in murine models.
Analysis of the APEX and CoMMpass datasets established a correlation between PSMC2 expression and adverse patient outcomes; this suggests potential as a therapeutic target.
Developing therapies that exploit proteasomal dependencies may provide new avenues to treat patients who fail standard treatments like bortezomib.